1. Электронный научный архив УрФУ
  2. 00. Общеуниверситетские коллекции
  3. Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC
Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/131238
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorChupakhin, O. N.en
dc.contributor.authorRusinov, V. L.en
dc.contributor.authorVaraksin, M. V.en
dc.contributor.authorUlomskiy, E. N.en
dc.contributor.authorSavateev, K. V.en
dc.contributor.authorButorin, I. I.en
dc.contributor.authorDu, W.en
dc.contributor.authorSun, Z.en
dc.contributor.authorCharushin, V. N.en
dc.date.accessioned2024-04-08T11:05:57Z-
dc.date.available2024-04-08T11:05:57Z-
dc.date.issued2022-
dc.identifier.citationChupakhin, ON, Rusinov, VL, Varaksin, MV, Ulomskiy, EN, Savateev, KV, Butorin, II, Du, W, Sun, Z & Charushin, VN 2022, 'Triazavirin—A Novel Effective Antiviral Drug', International Journal of Molecular Sciences, Том. 23, № 23, 14537. https://doi.org/10.3390/ijms232314537harvard_pure
dc.identifier.citationChupakhin, O. N., Rusinov, V. L., Varaksin, M. V., Ulomskiy, E. N., Savateev, K. V., Butorin, I. I., Du, W., Sun, Z., & Charushin, V. N. (2022). Triazavirin—A Novel Effective Antiviral Drug. International Journal of Molecular Sciences, 23(23), [14537]. https://doi.org/10.3390/ijms232314537apa_pure
dc.identifier.issn1661-6596-
dc.identifier.otherFinal2
dc.identifier.otherAll Open Access; Gold Open Access; Green Open Access3
dc.identifier.otherhttps://www.mdpi.com/1422-0067/23/23/14537/pdf?version=16692851351
dc.identifier.otherhttps://www.mdpi.com/1422-0067/23/23/14537/pdf?version=1669285135pdf
dc.identifier.urihttp://elar.urfu.ru/handle/10995/131238-
dc.description.abstractThis review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug. © 2022 by the authors.en
dc.description.sponsorshipNational Natural Science Foundation of China, NSFC, (20-53-55003, 82161148007)en
dc.description.sponsorshipRussian Foundation for Basic Research, РФФИen
dc.description.sponsorshipMinistry of Education and Science of the Russian Federation, Minobrnauka, (FEUZ-2022-0001)en
dc.description.sponsorshipThis work was supported by the Ministry of Science and Higher Education of the Russian Federation (Project No FEUZ-2022-0001), RFBR and NSFC (RFBR project No 20-53-55003, NSFC project number No 82161148007).en
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.publisherMDPIen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.rightscc-byother
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/unpaywall
dc.sourceInternational Journal of Molecular Sciences2
dc.sourceInternational Journal of Molecular Sciencesen
dc.subjectANTIVIRAL THERAPYen
dc.subjectCOVID-19en
dc.subjectRIAMILOVIRen
dc.subjectSARS-COV-2en
dc.subjectTRIAZAVIRINen
dc.subjectANIMALSen
dc.subjectANTIVIRAL AGENTSen
dc.subjectAZOLESen
dc.subjectCOVID-19en
dc.subjectENCEPHALITIS, TICK-BORNEen
dc.subjectHUMANSen
dc.subjectINFLUENZA, HUMANen
dc.subjectOSELTAMIVIRen
dc.subjectOXYGEN RADICALen
dc.subjectRIAMILOVIRen
dc.subjectANTIVIRUS AGENTen
dc.subjectPYRROLE DERIVATIVEen
dc.subjectAIRWAY EPITHELIUM CELLen
dc.subjectALKYLATIONen
dc.subjectANTIMICROBIAL ACTIVITYen
dc.subjectANTINEOPLASTIC ACTIVITYen
dc.subjectANTIVIRAL ACTIVITYen
dc.subjectANTIVIRAL THERAPYen
dc.subjectBILIRUBIN BLOOD LEVELen
dc.subjectBIOLOGICAL FUNCTIONSen
dc.subjectCHEMICAL REACTIONen
dc.subjectCLINICAL PRACTICEen
dc.subjectCOMPARATIVE STUDYen
dc.subjectCORONAVIRUS DISEASE 2019en
dc.subjectDISSOCIATION CONSTANTen
dc.subjectDRUG BIOAVAILABILITYen
dc.subjectDRUG EFFICACYen
dc.subjectELIMINATION HALF-LIFEen
dc.subjectHUMANen
dc.subjectHYDROGEN BONDen
dc.subjectINFLUENZA A VIRUS (H7N3)en
dc.subjectINFLUENZA A VIRUS (H9N2)en
dc.subjectINFLUENZA VIRUSen
dc.subjectKIDNEY FUNCTIONen
dc.subjectLUNG PARENCHYMAen
dc.subjectMOLECULAR MODELen
dc.subjectNITROSYLATIONen
dc.subjectNONHUMANen
dc.subjectOXIDATIVE STRESSen
dc.subjectOXYGEN BREATHINGen
dc.subjectPOLYMERASE CHAIN REACTIONen
dc.subjectREACTION TEMPERATUREen
dc.subjectREGIOSELECTIVITYen
dc.subjectREVIEWen
dc.subjectRIFT VALLEY FEVERen
dc.subjectRING OPENINGen
dc.subjectROOM TEMPERATUREen
dc.subjectRUSSIAN FEDERATIONen
dc.subjectSTATIC ELECTRICITYen
dc.subjectSTEREOSPECIFICITYen
dc.subjectSUBSTITUTION REACTIONen
dc.subjectTAUTOMERen
dc.subjectTICK BORNE ENCEPHALITISen
dc.subjectTICK BORNE ENCEPHALITIS VIRUSen
dc.subjectVIRUS REPLICATIONen
dc.subjectWEST NILE FEVERen
dc.subjectX RAY CRYSTALLOGRAPHYen
dc.subjectANIMALen
dc.subjectINFLUENZAen
dc.subjectTICK BORNE ENCEPHALITISen
dc.titleTriazavirin—A Novel Effective Antiviral Drugen
dc.typeReviewen
dc.typeinfo:eu-repo/semantics/reviewen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.3390/ijms232314537-
dc.identifier.scopus85143736704-
local.contributor.employeeChupakhin O.N., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federation, Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.contributor.employeeRusinov V.L., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federation, Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.contributor.employeeVaraksin M.V., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federation, Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.contributor.employeeUlomskiy E.N., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federation, Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.contributor.employeeSavateev K.V., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federationen
local.contributor.employeeButorin I.I., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federationen
local.contributor.employeeDu W., Department of Pharmacology, The Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin, 150086, Chinaen
local.contributor.employeeSun Z., Department of Pharmacology, The Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin, 150086, Chinaen
local.contributor.employeeCharushin V.N., Department of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federation, Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.issue23-
local.volume23-
dc.identifier.wos000897437000001-
local.contributor.departmentDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, Ekaterinburg, 620002, Russian Federationen
local.contributor.departmentInstitute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, Ekaterinburg, 620990, Russian Federationen
local.contributor.departmentDepartment of Pharmacology, The Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin, 150086, Chinaen
local.identifier.pure32888400-
local.identifier.purea2205dfe-145a-485a-b788-c0f8bd695a31uuid
local.description.order14537-
local.identifier.eid2-s2.0-85143736704-
local.identifier.wosWOS:000897437000001-
local.identifier.pmid36498864-
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85143736704.pdf8,35 MBAdobe PDFПросмотреть/Открыть
Показать базовое описание ресурса Статистика


Лицензия на ресурс: Лицензия Creative Commons Creative Commons